Multi-modal neurotrophic effects mimicking BDNF/CNTF signaling; protein synthesis modulation; neuroprotection in ischemia models.
Reference facts
- Also known as
- Porcine brain peptide complex
- Category
- Nootropic & Cognitive
- Mechanism of action
- Multi-modal neurotrophic effects mimicking BDNF/CNTF signaling; protein synthesis modulation; neuroprotection in ischemia models.
- Targets
- Multi-target neurotrophic signaling
- Indications under research or approved
- Approved Europe/Asia (ischemic stroke, vascular dementia, TBI); not US-approved
- Regulatory status (reference entry)
- Not FDA-approved
- Half-life
- Variable (mixture)
- Sequence notes
- Mixture of low-molecular-weight peptides and free amino acids (~85% free aa, 15% peptides <10 kDa) derived from enzymatic breakdown of porcine brain protein.
- Originator / sponsor
- Ever Neuro Pharma (Austria)
- First reported
- 1949
Primary References
Explore research articles about Cerebrolysin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.